Table 2 Multivariate analysis of TFS... | American Society of Hematology

Table 2

Multivariate analysis of TFS including the high-risk parameters studied

Parameter	HR	95% CI	P	HR	95% CI	P
Stage B/C	3.27	1.85–5.78	< .001	—	—	—
CD38⁺	.94	.51–1.72	.845	1.31	.76–2.27	.330
ZAP-70⁺	1.33	.78–2.26	.294	1.34	.79–2.27	.280
High-risk genomic aberrations	1.45	.84–2.51	.186	1.85	1.12–3.04	.016
IGHV unmutated	1.22	.65–2.29	.533	1.68	.91–3.12	.097
Short telomeres	1.98	1.10–3.56	.023	1.47	.88–2.45	.145

Parameter	HR	95% CI	P	HR	95% CI	P
Stage B/C	3.27	1.85–5.78	< .001	—	—	—
CD38⁺	.94	.51–1.72	.845	1.31	.76–2.27	.330
ZAP-70⁺	1.33	.78–2.26	.294	1.34	.79–2.27	.280
High-risk genomic aberrations	1.45	.84–2.51	.186	1.85	1.12–3.04	.016
IGHV unmutated	1.22	.65–2.29	.533	1.68	.91–3.12	.097
Short telomeres	1.98	1.10–3.56	.023	1.47	.88–2.45	.145